NSAID Rimifin Gets A New Taste

Pet owner compliance is critical to ensuring effective and continuing treatment in chronic conditions such as osteoarthritis. To help increase compliance, Rimifin, a NSAID marketed by Vetoquinol, has now got a new flavouring. Robert Simpson, Product Manager for Rimifin comments, “Pet owner compliance and involvement in chronic pain situations is critical to ensuring effective long term treatment. Ease of administration is also very important in this setting. The addition of this flavouring to this popular and cost effective NSAID will help to ensure that administration to the patient is as easy as possible for pet owners and vets.” To find out more about Rimifin please contact your Vetoquinol Territory Manager or call 01280 825424. Rimifin is a non-steroidal anti-inflammatory drug (NSAID) which contains carprofen (POM-V). For further information on Rimifin please contact Vetoquinol directly.

More from

• Vetsure Named Business of the Year at 2025 SME National Business Awards
• Home of hope for Romania's dogs: The pioneering shelter doing things differently
• Pioneering new locum platform transforming veterinary landscape
• Key Stakeholders unite to advance helmet design for equine veterinary professionals
• Hallmarq hails transformational equine imaging technology